General Motors (GM): The unmanned business Cruise and GM Technical team will be merged, and the plan is expected to be completed in the first half of 2025. According to the priority of GM's capital allocation, GM will no longer fund Cruise's self-driving taxi development business.Japanese and Korean stock markets opened slightly lower, with the Nikkei 225 index down 0.02% at 39,357.77. South Korea's KOSPI index opened down 0.2% to 2,412.15 points.NVIDIA's market value evaporated by 660 billion yuan overnight. On December 10th, local time, the three major US stock indexes collectively closed down, with the Dow down 0.35%, the Nasdaq down 0.25% and the S&P 500 index down 0.30%. Among them, NVIDIA fell by 2.69%, and its market value evaporated by 91.593 billion US dollars (about 664.047 billion yuan) overnight.
Kathy Hochul, the governor of New York, said that a governor's arrest warrant would be issued to the suspect who murdered the CEO of United Health Insurance.Galaxy Securities: The equity market rebounded, and the improved double-low strategy exceeded 9% during the year. According to china galaxy Securities, the last cycle (11.26-12.9) recorded 2.3%, 1.7% and 3.2% respectively (the benchmark for the same period was 2.7%). Since the beginning of this year, the performance of the three types of strategies has been 8.5%, 8.6% and 15.1% respectively (the benchmark for the same period is 6.6%), and the cumulative excess rate of return is 2-9%. In the last cycle, the equity market rebounded and repaired. Wandequan A rose by 4.05%, and CSI convertible bonds followed (2.68%), among which the double-low style (3.25%) rose higher, and the low-price enhancement and low-price large-market strategy slightly underperformed the benchmark, and the double-low improvement strategy continued to dominate.
Guohai Securities gave Youyou Food Co., Ltd. the initial rating of buying.Guotai Junan's annual strategy for innovative drugs in 2025: innovative pharmaceutical companies have accelerated into the harvest period, and the valuation has been at a historical low in the past five years. Guotai Junan said that the centralized purchasing policy has become stable, mature and normalized, and the marginal impact has weakened. Innovative drugs have gained policy inclination in the medical insurance negotiation. In the past two years, the policy has continued to promote pharmaceutical innovation, and the top-level design and local supporting chain support the development of innovative drugs. Commercial insurance is expected to bring new growth momentum to China's pharmaceutical market, and the overall industry trend is upward. At present, the trend of innovative drug industry is improving, the supply continues to accelerate, and a number of domestic innovative drugs are approved soon, which is expected to drive a new round of heavy volume. At the same time, the commercialization has achieved remarkable results and has occupied a dominant position in some sub-sectors. Pharma's performance continued to differentiate, and innovative drugs and just-needed drugs performed well. Biotech commercialization continues to increase, per capita yield continues to increase, the node of turning losses is approaching, and innovation ushers in the harvest period. Horizontal comparison: compared with overseas peers, the overall valuation of domestic innovative pharmaceutical companies is in a historically low range; Vertical comparison: the valuation of SW- pharmaceutical biology and SW- chemical preparations is at a historical low in the past five years, and it is expected that the valuation of subsequent sectors will pick up.Policy combination boosts confidence, and public offering: China's assets will usher in a further increase in valuation. On December 9, the Political Bureau of the Communist Party of China (CPC) Central Committee held a meeting to analyze and study the economic work in 2025. A number of public offerings said that the meeting sent a very positive signal. At present, the economy is resilient, the investor structure is constantly optimized, and the market activity continues to increase. China assets may have an opportunity to raise their valuations again. From the perspective of funds, Jing Shun Great Wall Fund analyzed that the current A-share market is in the most active stage since 2015, and there are many potential bulls in the market. Policy expectations are expected to drive incremental funds into the market, forming a resonance between emotions and funds. (SSE)
Strategy guide 12-13
Strategy guide 12-13
Strategy guide 12-13